Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients

Simone Manca-di-Villahermosa, Roberto Giacominelli-Stuffler, Clotilde B. Angelucci, Massimo Taccone-Gallucci, Mauro Maccarrone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.

Original languageEnglish
Pages (from-to)229-240
Number of pages12
JournalRecent Patents on Inflammation and Allergy Drug Discovery
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Arachidonate 5-Lipoxygenase
Vitamin E
Renal Dialysis
Monocytes
Maintenance
Secondary Prevention
Atherosclerosis
Primary Prevention
Cardiovascular Diseases
Lipoxygenase Inhibitors
Patents
Platelet Aggregation
LDL Lipoproteins
Chronic Kidney Failure
Smooth Muscle Myocytes
Epidemiologic Studies
Antioxidants
Cell Proliferation
Cytokines

Keywords

  • 5-lipoxygenase
  • Cardiovascular disease
  • Hemodialysis
  • Outcomes
  • Oxidative stress
  • Vitamin E

ASJC Scopus subject areas

  • Drug Discovery
  • Immunology and Allergy

Cite this

Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients. / Manca-di-Villahermosa, Simone; Giacominelli-Stuffler, Roberto; Angelucci, Clotilde B.; Taccone-Gallucci, Massimo; Maccarrone, Mauro.

In: Recent Patents on Inflammation and Allergy Drug Discovery, Vol. 5, No. 3, 09.2011, p. 229-240.

Research output: Contribution to journalArticle

Manca-di-Villahermosa, Simone ; Giacominelli-Stuffler, Roberto ; Angelucci, Clotilde B. ; Taccone-Gallucci, Massimo ; Maccarrone, Mauro. / Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients. In: Recent Patents on Inflammation and Allergy Drug Discovery. 2011 ; Vol. 5, No. 3. pp. 229-240.
@article{120a854c67eb439ab1dbe30a96d2a109,
title = "Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients",
abstract = "A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.",
keywords = "5-lipoxygenase, Cardiovascular disease, Hemodialysis, Outcomes, Oxidative stress, Vitamin E",
author = "Simone Manca-di-Villahermosa and Roberto Giacominelli-Stuffler and Angelucci, {Clotilde B.} and Massimo Taccone-Gallucci and Mauro Maccarrone",
year = "2011",
month = "9",
doi = "10.2174/187221311797264892",
language = "English",
volume = "5",
pages = "229--240",
journal = "Recent Patents on Inflammation and Allergy Drug Discovery",
issn = "1872-213X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Vitamin E-related inhibition of monocyte 5-lipoxygenase and cardiovascular outcome in maintenance hemodialysis patients

AU - Manca-di-Villahermosa, Simone

AU - Giacominelli-Stuffler, Roberto

AU - Angelucci, Clotilde B.

AU - Taccone-Gallucci, Massimo

AU - Maccarrone, Mauro

PY - 2011/9

Y1 - 2011/9

N2 - A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.

AB - A daily supplement of vitamin E is recommended for the secondary prevention of cardiovascular events in end-stage renal disease patients on maintenance hemodialysis. Vitamin E has been entrusted with therapeutic properties against cardiovascular disease for more than 60 years. Several epidemiological studies and intervention trials have been performed with vitamin E, and some of them showed that it prevents atherosclerosis. For a long time, vitamin E was assumed to act by decreasing the oxidation of low-density lipoproteins, a key step in atherosclerosis initiation. However, at the cellular level vitamin E interferes with smooth muscle cell proliferation, platelet aggregation, monocyte adhesion, and oxidized low-density lipoproteins uptake and cytokine production, all reactions implied in the progression of atherosclerosis. Recent research points out that these effects may be not only the result of the antioxidant activity of vitamin E but also of its distinct molecular actions. These biological properties of vitamin E may allow to design better strategies for primary and secondary prevention of cardiovascular disease, with a potential exploitation of vitamin E supplements in primary and secondary prevention of major adverse cardiovascular events in all uremic patients. In this review, we also outline relevant patents on vitamin E and lipoxygenase inhibitors.

KW - 5-lipoxygenase

KW - Cardiovascular disease

KW - Hemodialysis

KW - Outcomes

KW - Oxidative stress

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=80052832327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052832327&partnerID=8YFLogxK

U2 - 10.2174/187221311797264892

DO - 10.2174/187221311797264892

M3 - Article

C2 - 21843148

AN - SCOPUS:80052832327

VL - 5

SP - 229

EP - 240

JO - Recent Patents on Inflammation and Allergy Drug Discovery

JF - Recent Patents on Inflammation and Allergy Drug Discovery

SN - 1872-213X

IS - 3

ER -